AstraZeneca Nexium Prescriptions Grow 19%; Discounts Still Capturing “Value” For Brand

“We are far from being in a position of valueless volume growth,” AstraZeneca says, despite fierce competition in PPI category. Nexium sales are “virtually unchanged” in U.S. during first quarter; AstraZeneca cites inventory comparisons, not pricing, as reason.